HRS-9813
Phase 2Small molecule
Guangdong Hengrui Pharmaceutical Co., LtdHRS-9813 is one of 10 small molecule programs targeting Pulmonary Fibrosis. It is currently in Phase 2.
1
Indications
5
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Remodulin
United TherapeuticsApproved
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Ofev
Boehringer IngelheimPhase 3
BMS-986278
Bristol-Myers SquibbPhase 3
CBP8
MMassachusetts General Hospital
Phase 2
HRS-9813
Guangdong Hengrui Pharmaceutical Co., LtdPhase 2
Corticosteroids Alone
MMansoura University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HRS-9813. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details